NovAliX Joins Hands With Max Planck Institute on Cancer Pact

NovAliX, a specialized contract research company that is committed to facilitating drug development, has entered into a long-term strategic cooperation with the Max Planck Institute (MPI) for Multidisciplinary Sciences in Gottingen.

NovAliX and the MPI hope that by working together, they will be able to improve the efficiency of the crucial process of turning scientific research and intellectual ideas into actual therapies.

Prof. Dr. Holger Stark, the Managing Director at the Max Planck Institute, talked about the potential of this collaboration to take the drug discovery field to the next level in terms of innovation and groundbreaking advancements. He said, “The endpoint of fundamental academic research is still considerably distant from the initial stages of drug discovery. Bridging these phases is substantially important; the MPI’s and NovAliX’s complementary expertise will be essential for fostering successful therapeutic development.”

Through this collaborative effort, vital early-stage collaboration will be made possible, combining the potential of the ground-breaking discoveries made by MPI specialists with the distinguished scientists of NovAliX. This will also help expedite the incorporation of academic ideas into the process of medication development.

Dr. Denis Zeyer, the CEO of NovAliX, emphasized the significance of collaborative partnerships between academic institutions and drug discovery, citing his twenty years of involvement in the ever-evolving biopharmaceutical sector. He noted that the process of identifying and introducing new medicines to the market has become increasingly expensive and risky, rendering the current model unsustainable. He highlighted that involving academic research more extensively in the drug discovery process can enhance the likelihood of success in identifying therapeutic applications.

Dr. Zeyer also highlighted the paramount importance of nurturing relationships established over time, emphasizing that NovAliX places immense value on these connections as a result of its origins within academic institutions. He specifically mentioned the enduring partnership with Prof. Dr. Stark at the MPI for Multidisciplinary Sciences, along with their ongoing collaborative efforts in exploring the realm of Cryo-EM, as exemplars of this deep-rooted value.

Cryo-electron microscopy, or cryo-EM, is a type of imaging technology that allows for the atomic-level visualization of the structures of biomolecules. Flash-freezing biological specimens, imaging them using an electron microscope, and then rebuilding the pictures into a three-dimensional model are all steps involved in this process.

Contract research organizations like NovAliX have established themselves as key actors in the drug discovery business. These companies offer the organizational structure, flexibility, competence, and efficiency that are necessary for early-stage pharmaceutical studies. Within the context of the ever-changing environment of drug development, this partnership with the MPI marks their growing position as active partners, making it possible for academic research to contribute to the realization of therapeutic innovation.

Stephan Jenn, co-founder of NovAliX, characterized the collaboration with the MPI as an exceptional opportunity to establish a distinctive alliance that not only advances European scientific progress but also contributes on a global scale. He emphasized the importance of engaging top minds from both academia and drug development in enhancing scientific advancements, achieving superior outcomes, and providing more effective solutions.